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Electron MicroscopyGliomas still represent a serious and discouraging brain tumor; despite of the diversity of therapeutic
modalities, the prognosis for patients is still poor. Understanding the structural and functional characteristics
of the vascular microenvironment in gliomas is essential for the design of future therapeutic strategies. This
review describes and analyzes the electron microscopy morphology of the mitochondrial network in human
gliomas and their vascular microenvironment. Heterogeneous mitochondrial network alterations in glioma
cells and in microvascular environment are implicated directly and indirectly in the processes linked to
hypoxia-tolerant and hypoxia-sensitive cells phenotype, effects of the hypoxia-inducible factor-1α, increased
expression of several glycolytic protein isoforms as well as fatty acid synthase, and survivin. The prevalent
existence of partial or total cristolysis observed suggests that oxidative phosphorylation is severely
compromised. Amixed therapy emerged as themost appropriate. This article is part of a Special Issue entitled:
Bioenergetics of Cancer.ergetics of Cancer.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
In 1857 Rudolf Albert von Kölliker (1817–1905), histologist and
embryologist, ﬁrst described “sarcosomes” (now calledmitochondria)
in muscle cells. Kölliker was among the ﬁrst biologists to interpret
tissue structure in terms of cellular elements. The term “mitochon-
drion” (meaning “threadlike granule”) was ﬁrst used in 1898. In the
1930s, Warburg described increased rates of glycolysis and mito-
chondrial defects in cancer cells. Functionally active mitochondria
were ﬁrst isolated in 1948. In the 1950s, mitochondria were observed
by means electron microscopy. Today, after 120 years, the study of
mitochondria is a central issue in numerous human diseases.
In the last decade, advances in light and electron microscopy have
led to a renewed interest in the structural diversity and dynamics of
mitochondria, as well as in their interactions with other cellular
components [1]. Some connections exist between cancer and mito-
chondria. In cancer, mitochondrial changes are associated with
mitochondrial-DNA mutations, tumoral microenvironment conditions
and mitochondrial fusion–ﬁssion disequilibrium. Mitochondrial struc-
ture and functions vary from tissue to tissue. The mitochondrial
morphology is modiﬁed by functional requirements to adapt to
different cell demands. On the other hand, in cancer cells, dysfunctional
mitochondria are implicated directly or indirectly in their limitless
replication, self-provision of proliferative stimuli, insensitivity toantiproliferative signals, disable apoptosis, sustained angiogenesis,
invasiveness, avoidance of the immune response, and enhance anabolic
metabolism [2]. In human tumors and tumoral cell lines, mitochondria
show conspicuous alterations in their ultrastructural aspects [3].
Today, gliomas still represent a serious and discouraging brain
tumor; despite of the diversity of treatment modalities, generally, the
prognosis for patients is still poor (i.e. fatality and sequelae). One of
the major conceptual advances in oncology over the last decade has
been the appreciation that all major aspects of cancer biology are
inﬂuenced by the tumor microenvironment [4]. The tumor microen-
vironment is a mixture of extracellular matrix molecules, tumor cells,
endothelial cells, ﬁbroblasts and immune cells [5]. Angiogenesis and
continuous remodeling of the tumor microvasculature are essential
for adequate tumor tissue oxygenation and nutritional supply [6].
According to Vajkoczy and Menger [6], the vascular microenviron-
ment determines pathophysiological characteristics of gliomas and
the structure and function of the glioma microvasculature determine
susceptibility and resistance of the tumor to speciﬁc treatment
strategies [6]. Furthermore, the understandings of these aspects in
gliomas are basic for the design of pharmacological treatments.
Mitochondrial structural abnormalities and dysfunction in malig-
nant gliomas are a neglected area of research [7]. The understanding
of structural and functional characteristics of the vascular microen-
vironment in gliomas is essential for the design of future therapeutic
strategies. Electron microscopy permits the study of mitochondrial
morphology and their overall organization. The aim of this review is to
describe and analyze the electron microscopy morphology of the
mitochondrial network in human gliomas and their vascular
603G. Arismendi-Morillo / Biochimica et Biophysica Acta 1807 (2011) 602–608microenvironment, and probably represent a contribution to the
structural basis of several mitochondrial molecular defects reported in
gliomas that would be explaining, at least in part, the resistance of
astrocytic tumors to conventional chemotherapy.
2. Electron microscopy morphology of the mitochondrial network
and functional implications in human glioma cells and
vascular microenvironment
2.1. Mitochondrial pathology in tumoral cells
Mitochondrial swelling associated with disarrangement of cristae
and partial or total cristolysis is the most constant submicroscopic
alteration observed in gliomas (Fig. 1). In pilocytic astrocytomas
particularly, in addition to swelling mitochondria, mitochondria with
increased thickness and remarkably electron dense cristae were seen,
as well as in undifferentiated neoplastic cells. On the other hand,
ﬁbrillary astrocytomas, anaplastic astrocytoma and glioblastoma
multiforme show that mitochondrial swelling associated with
disarrangement of cristae and partial or total cristolysis is the most
constant ultrastructural ﬁnding. However, non-speciﬁc ultrastructural
differences between the different grades of tumors exist. This
morphological change is associated with hypoxic–ischemic condi-
tions [8], and it is well known that hypoxic microenvironment is a
characteristic of human gliomas [9,10]. Since the enzymes involved in
oxidative phosphorylation are located on the inner mitochondrial
membrane, its surface area and number of cristae are generally
correlated with the grade of metabolic activity exhibited by a cell [11].
Gilkerson et al. [12], using immunolabeling and transmission electron
microscopy of bovine heart tissue, estimated that the crystal mem-
brane of mitochondria is the principal site of oxidative phosphory-
lation. Diversity of tumors exhibits an evident diminution in
mitochondrial content [13,14] and in oxidative phosphorylation
capacity [15,16]. Oudard et al. [13] reported a very low content of
normally functioning mitochondria in 4 human xenografted gliomas
and suggest that gliomas shift the energy metabolism towards a high-
level glycolysis to generate their cellular ATP supply. Therefore, the
prevalent existence of partial or total cristolysis observed in this study
suggests consequently that the ability of human astrocytomas to
generate ATP by mitochondrial oxidative phosphorylation would be
severely compromised, therefore, to a low bioenergetic index. In
addition, this would deteriorate the ability of astrocytoma cells to
commit apoptosis. Recently, Chiche et al. [17] reported that hypoxic
enlarged mitochondria protect cancer cells from apoptotic stimuli.
This ﬁnding is congruent with infrequently observed ultrastructural
morphologic changes suggestive of apoptosis observed in astrocytic
tumors [18], in accordance to the ultrastructural criteria for apoptosis
previously established [19]. This aspect is consistent with the earlier
detection that human malignant glioma cells undergo necrosis ratherFig. 1.Mitochondrion exhibits a cristae disarrangement, partial cristolysis and electron-
lucent matrix in a tumoral cell. Method of staining: uranile acetate/lead citrate. Bar:
3.32 μm.than apoptosis because of energy deprivation, reported by Steinbach
et al. [8]. In addition, Steinbach and Weller [20] previously point out
that the amount of apoptosis is generally low in malignant gliomas.
On the other hand, Cuezva et al. [14] mentioned that cancer cells with
a low bioenergetic index as a result of a low mitochondrial content
and/or activity would be prone to establish a transformed phenotype
and become more resistant to apoptosis.
In some astrocytoma cells, a predominant presence of mitochon-
dria with dense matrix displayed in closed groups exists (Figs. 2
and 3). In other astrocytoma cells, the principal ﬁnding is the lucent-
swelling mitochondria with disarrangement and distortion of cristae
and partial or total cristolysis. Recently, Rossignol et al. [21] illustrated
that mitochondria of HeLa cells and ﬁbroblast adopt a condensed
conﬁguration when producing energy by oxidative phosphorylation.
In the case of astrocytomas, the dense mitochondria could be capable
of producing energy by oxidative phosphorylation, and lucent-
swelling mitochondria with disarrangement and distortion of cristae
and partial or total cristolysis are incapable of generating energy by
oxidative phosphorylation. Parliament et al. [22] postulated that
glioma cell lines behave as “oxygen conformers” and their rate of
oxygen consumption appears to vary with the availability of oxygen.
Turcotte et al. [23] demonstrated variation in mitochondrial function
in hypoxia-sensitive and hypoxia-tolerant human glioma cells.
Possibly, the astrocytoma cells that hold dense mitochondria are
hypoxia-tolerant cells, therefore, able to generate sufﬁcient ATP
concentration by oxidative phosphorylation. In contrast, the astrocy-
toma cells that contain lucent-swelling mitochondria with disar-
rangement and distortion of cristae and partial or total cristolysis are
hypoxia-sensitive cells, therefore, incompetent to produce adequate
amount of ATP by mitochondrial respiration.
In gliomas, mitochondria show variability in number, size and
shape, included in the same specimen, as well as the degree of severity
of internal ultrastructural mitochondrial changes. Somemitochondria
exhibited cigar, bowling-pin, ‘L’, ‘V’, ‘Y’ and irregular shapes (Fig. 4).
Possibly, this is related with the cellular variability of astrocytomas
and variations in microenvironment conditions, i.e., diverse degree of
hypoxia, pH, and hypoglycemia, and ﬁnally if the astrocytoma cells are
hypoxia-tolerant or hypoxia-sensitive. Earlier, Tandler et al. [24]
suggested that the existence of extremely pleomorphism and normalFig. 2. Mitochondria with dense matrix displayed in closed group in a tumoral cell.
Method of staining: uranile acetate/lead citrate. Bar: 1.62 μm.
Fig. 3. Mitochondria demonstrate increased thickness and remarkably electron dense
cristae in tumoral cells. Method of staining: uranile acetate/lead citrate. Bar: 5.68 μm.
Fig. 5. Lipid droplet (asterisk) is next to mitochondria with dense matrix in a tumoral
cell. Method of staining: uranile acetate/lead citrate. Bar: 2 μm.
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development of the mature oncocyte. On the other hand, the
mitochondrial morphology is modiﬁed by functional requirements
to adapt to different cell demands. Recently, Smolkova et al. [25]
proposed the “metabolic waves hypothesis”, wherein cancer cells will
exhibit differences in energy metabolism depending on oncogene
activation and environmental factors, this might also explain the
diverse changes in mitochondrial shape.
Lipid droplets between or near themitochondria are present (Figs. 5
and 6). Accumulation of lipid droplets is observed in infectious,
neoplastic and inﬂammatory conditions [26]. Apparently, the lipid
droplets are inducible organelles with roles in cell signaling, regulation
of lipid metabolism, membrane trafﬁcking and control of the synthesis
and secretion of inﬂammatory mediators [26]. In many human cancers,
lipogenic pathways are activated, and the lipid droplets are the
ultrastructural expression of these biochemical phenomena [27]. In
gliomas, increased expression of fatty acid synthase has been observed,
and the inhibition of this enzyme is associated with decreased glioma
cell viability [28]. Transmission electron microscopy showed that lipid
droplets were present in the necrotic and perinecrotic areas of the C6
cell-induced rat glioma [28,29]. According to Delikatny et al. [30] the
lipid droplets are likely to be indicators of a reduction in mitochondrial
metabolic activity. In addition, Zoula et al. [31] described that severe
hypoxic C6 rat brain glioma showed accumulated small lipid droplets,Fig. 4.Mitochondria show variable size and shape in tumoral cells. Method of staining:
uranile acetate/lead citrate. Bar: 3 μm.however it cannot be considered as a surrogate marker of hypoxia. C6
glioma cells proliferation arrest induced by growth factors deprivation
induces an even higher accumulation of cytosolic droplets [32]. Opstad
et al. [33] show in human gliomas that the distribution of the lipid
droplets is independent of the tumor grade, as well as a positive
correlation with the percentage of necrosis and that the formation of
lipid droplets precedes necrosis.
Mitochondrial morphology is regulated by continuous fusion and
ﬁssion events that are essential for maintaining a normal mitochondrial
function [34]. Mitochondrial fusion–ﬁssion phenomena are scarce in
gliomas [18]. These mitochondria exhibit edematous changes and
cristolysis; morphological changes that suggest loss of the mitochon-
drial inner membrane potential and serious defect in the respiratory
chain. Mitochondrial ﬁssion accompanies several types of apoptotic cell
death and appears important for progression of the apoptotic pathway
[35]. Different mitochondrial alterations observed in cancer cells could
be linked to unbalancedmitochondrial ﬁssion or fusion events [34]. The
low frequency of mitochondrial ﬁssion observed in gliomas is in
concurrence with the fact that the amount of apoptosis is generally low
inmalignant gliomas [20]. Survivin is a molecule expressed by themost
human cancers; acts as an inhibitor of apoptosis in cancer and
coordinates a pathway of apoptosis inhibition [36,37]. The interference
of survivin expression induces remarkable apoptosis in glioma cell line
U251 [38]. Blum et al. [39] reported that the suppression of survivin
expression in U87 glioblastoma multiforme cells by the Ras inhibitor
farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mi-
tochondria in astrocytomas probably produce survivin, this potentially
explains the lowoccurrence ofmitochondrial ﬁssion and ultrastructural
morphologic changes suggestive of apoptosis in human gliomas [18]. In
addition, growingevidence suggests that survivin is responsible fordrug
resistance in cancer cells [40].Fig. 6. Lipid droplets (ld) in close proximity to mitochondrion with multiple alterations
in a tumoral cell. Method of staining: uranile acetate/lead citrate. Bar: 1 μm.
Fig. 7.Mitochondrion shows crystalline intermembrane inclusions in tumoral cell. Note
the dense matrix in other mitochondrion. Method of staining: uranile acetate/lead
citrate. Bar: 5.7 μm.
Fig. 9. Mitochondrial crystalline intermembrane inclusions exhibit a lattice pattern
alternating electron dense and electron lucent bands. Method of staining: uranile
acetate/lead citrate. Bar: 0.83 μm.
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They exhibit a lattice pattern alternating electron dense and electron
lucent bands. In the context of the gliomas, possibly their apparition is
linkedwith hypoxic conditions. These kinds ofmitochondrial inclusions
represent crystallization ofmembrane proteins and a disturbance in the
respiratory pathway, and are linked with tissular ischemia, inﬂamma-
tory, metabolic, and neoplastic and neurodegenerative illness. Intrami-
tochondrial lamellar bodies or paracrystalline inclusion were reported
in acute myeloblastic leukemia, subependymal giant cell astrocytoma,
anaplastic oligoastrocytoma, and granular cell astrocytoma [41–44].
Crystal-like intramitochondrial inclusions in sporadic Parkinson's and
Alzheimer's disease hybrid cell lines were observed [45]. However, the
mechanism of formation and the pathophysiologic signiﬁcance of these
abnormal mitochondria remain unknown.
In human gliomas the presence of mitochondria that display a few
concentric layers of double leaﬂets of inner mitochondrial membrane
contained inside a continuous envelope of outer membrane (onion
ring-like structure) is scarce. This mitochondrial morphology is linked
with the loss of subunit e or g of the mitochondrial ATP synthase in
yeast cells [46,47]. The ATP synthase-associated subunits e and g are
indispensable for the biogenesis of the mitochondrial cristae [46]. The
full loss of subunit e or g decreased the mitochondrial ATPase activity
by 50% [47]; however, it is not sufﬁcient to affect growth by oxidative
phosphorylation [48]. Possibly, in the case of the cancer cells, the
contribution to energy metabolism of this rare mitochondrial con-
formation is not substantial, due to the amount and their apparentlyFig. 8. Higher magniﬁcation demonstrates crystalline intermembrane inclusions with
mitochondrial cristae vestige (arrows). Note an adjacent lipid droplet (ld) and
minuscule intramitochondrial myelin-like ﬁgure (circle). Method of staining: uranile
acetate/lead citrate. Bar: 0.6 μm.diminished energy production because of defective oxidative
phosphorylation.
Finally, in cell processes the presence of mitochondria is scarce.
This ﬁnding probably implies that at this level, the energy derived
from mitochondrial respiration is marginal. Beckner et al. [49]
reported that glycolitic enzymes are abundant in pseudopodia formed
by U87 astrocytoma cells, and that glycolysis alone can support glioma
cell migration. Recently, robust migration of glioblastoma cells has
been previously demonstrated under glycolytic conditions and their
pseudopodia contain increased glycolytic and decreased mitochon-
drial enzymes [50].
Someof the changes in themitochondria observed inhumangliomas
had been reported in other human cancer [3].
2.2. Mitochondrial alterations and morphological changes in the vascular
microenvironment components
The structural characteristics of the vascular microenvironment in
gliomas seem to be determined by both the tumor milieu and local
tissue factors [6]. As a result themicrovasculature components exhibit
conspicuous changes and their morphology is highly heterogeneous
when compared to normal cerebral vessels [51–58]. During develop-
ment of gliomas the microvasculature becomes aberrant [59]. This
aspect possibly is linked with the characteristic topographic variation
in the histopathological patterns displayed by astrocytic tumors,
regional angiogenic activity, constant remodeling of the tumor
microvasculature, and size of the tumor [6].
In the vascular microenvironment components of gliomas, the
mitochondrial network exhibit similar changes to describe in tumoral
cells. The mitochondria display mainly two patterns: a) swelling
associatedwith disarrangement of cristae and partial or total cristolysis;
and b) condensed conﬁguration (Figs. 10–14). The endothelial cells
present edematous andoncotic changes in variable grade, lipid droplets,
and alterations in tight junctions. Pericytes exhibit edematous changes
and phagocytosed material. Astrocytic perivascular-feet show signs ofFig. 10. Tumoral microvessel. Mitochondria on endothelial cells present dense matrix
displayed in closed group (circle), observe four electron-dense thigh junctions
structurally closed (opposed arrows). Perivascular cells process exhibit mitochondria
with dense matrix (bold arrows). Method of staining: uranile acetate/lead citrate. Bar:
6.66 μm.
Fig. 11. Sector of a tumoral microvessel. Mitochondria on endothelial cells (EC) and
pericyte (P) present dense and lucent matrix displayed in closed group. Note two
electron-dense thigh junctions structurally closed (opposed arrows). Pericyte exhibit
phagocytosed material. Asterisks identify basal membrane. Method of staining: uranile
acetate/lead citrate. Bar: 2.5 μm.
Fig. 13. Region of a tumoral microvessel. Mitochondria on endothelial cells (EC) and
pericyte (P) exhibit cristae disarrangement, partial and total cristolysis and electron-
lucent matrix (asterisks). Note a huge lipid droplet (ld) in close proximity to
mitochondria. BM denotes a multilayered basal membrane. Method of staining: uranile
acetate/lead citrate. Bar: 3.32 μm.
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es [60]. Unger et al. [61] demonstrated the presence of large number of
mitochondria in brain tumor-derived endothelial cells in culture. Caruso
et al. [62] described swollen mitochondria and cytoplasmic lucency in
three cases of human gastric carcinoma with coagulative necrosis.
Electronmicroscopic studies have identiﬁed structural alterations in
tight junctions [53–55,58,60–65]. In the perspective of an intratumoral
hypoxic medium, probably the anoxic–hypoxic conditions of the
neoplastic tissue constitute an actin-disregulating and actin-disrupting
factor that contribute with the changes in actin distribution patterns,
these latter ﬁnally induce the abnormalities observed in tight junctions
in astrocytic tumors. The observation of oncotic and ischemic changes in
endothelial, pericytes, and astrocytic perivascular end-feet denotes the
intratumoral developmentof hypoxic–anoxic conditions ingliomas. The
capillary endothelial cells are quite vulnerable to short periods of anoxia
[66]. Gliomas express the hypoxia-inducible factor-1α [67–70]. The
hypoxia-inducible factor-1α is involved in the resistance against
apoptosis, vascular remodeling and angiogenesis. In cancer cells, this
factor induces overexpression and increases activity of several glycolytic
protein isoforms, including transporters and enzymes [71]. Some of
these glycolitic isoforms participate in survival pathways, inhibition of
apoptosis and promotion of cell migration, modulate mitochondrial
function and oxygen consumption by inactivating the pyruvate
dehydrogenase complex in some tumors types, or by modulating
cytochrome c oxidase subunit 4 expression to increase oxidative
phosphorylation in other cancer cell lines [71]. In the cases ofmalignantFig. 12. Section of a tumoral microvessel. Mitochondria on endothelial cells (EC) exhibit
cristae disarrangement, partial and total cristolysis and electron-lucent matrix
displayed in closed group. Note a lipid droplet (ld) in close proximity to mitochondria.
Method of staining: uranile acetate/lead citrate. Bar: 3.32 μmgliomas, the inhibition of the hypoxia-inducible factor-1α decreases
vascular endothelial growth factor secretion and tumor growth [72].
Finally, Survivin is constitutively overexpressed in the glioma
vasculature [40,73], and confers chemoresistance to endothelial cells.
Therefore, the inhibition of this molecule may be an effective
approach to chemosensitization [40].
3. Perspectives for pharmacological therapeutics
Mitochondrial network alterations in glioma cells and in micro-
vascular environment are heterogeneous, and are implicated directly
and indirectly in the processes linked to hypoxia-tolerant and
hypoxia-sensitive cells phenotype, effects of the hypoxia-inducible
factor-1α, increased expression of several glycolytic protein isoforms
as well as fatty acid synthase, and survivin. Consequently, a mixed
therapy emerged as the most appropriate.
An approach would be target glycolysis and/or revert the Warburg
phenomenon. The glycolytic inhibitors are particularly effective
against cancer cells with mitochondrial defects or under hypoxic
conditions, which are frequently associated with cellular resistance to
conventional anticancer treatments and radiation therapy [74,75].
Griguer et al. [76] described oxidative phosphorylation-dependent
cells and glycolytic-dependent cells in human and mouse malignant
glioma cell lines. Therefore, the glycolysis inhibitionwould be effective
in hypoxia-sensitive cells. While the hypoxia-tolerant cells potentiallyFig. 14. Sector of microvessel. Mitochondria on pericyte (P) exhibit electron-dense
matrix. EC denotes endothelial cell, asterisks basal membrane, and L vessel lumen.
Method of staining: uranile acetate/lead citrate. Bar: 1.16 μm.
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mitochondrial respiration, given that mitochondrial insult or failure
can rapidly lead to inhibition of cell survival and proliferation [77,78].
At the vascular environment, since the numerous effects of the
hypoxia-inducible factor-1α, the inhibition or down-regulation in
endothelial cells and pericytes is a promising alternative. For the
chemosensitization, the blockage of the survivin effects also appears
as important issue.
Finally, changing the metabolic environment of the glioma by
means of dietary restrictions is recommended for the antiangiogenic
and pro-apoptotic properties [79,80].
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